CytomX Therapeutics Inc (CTMX):企業の財務・戦略的SWOT分析

◆英語タイトル:CytomX Therapeutics Inc (CTMX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH233460FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥68,400見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥102,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CytomX Therapeutics Inc (CytomX) is a clinical-stage biopharmaceutical company which develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, probody drug conjugate, and T-cell bispecific. CX-072, currently under Phase 1/2 clinical trial, is a PD-L1 targeting Probody therapeutic for the treatment of cancer. CX-2009, currently under Phase 1/2 trial, is a CD166-directed PDC for the treatment of cancer. BMS-986249, under Phase 1/2 clinical trial, is a CTLA-4-directed Probody therapeutic intended for the treatment of solid cancers. CX-2029, under Phase1/2 clinical trial, is a PDC directed against CD71 intended for the treatment of B-cell lymphoma. CX-188, under preclinical studies, is a PD-1-targeting Probody therapeutic. The company partners with other pharmaceutical companies to develop its novel therapeutics. CytomX is headquartered in South San Francisco, California, the US

CytomX Therapeutics Inc Key Recent Developments

Mar 24,2021: CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
Feb 24,2021: CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 22,2021: CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences
Feb 17,2021: CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
Feb 04,2021: CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day

This comprehensive SWOT profile of CytomX Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of CytomX Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

CytomX Therapeutics Inc – Key Information
CytomX Therapeutics Inc – Overview
CytomX Therapeutics Inc – Key Employees
CytomX Therapeutics Inc – Key Employee Biographies
CytomX Therapeutics Inc – Key Operational Heads
CytomX Therapeutics Inc – Major Products and Services
CytomX Therapeutics Inc – History
CytomX Therapeutics Inc – Company Statement
CytomX Therapeutics Inc – Locations And Subsidiaries
CytomX Therapeutics Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

CytomX Therapeutics Inc – Business Description
CytomX Therapeutics Inc – Corporate Strategy
CytomX Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
CytomX Therapeutics Inc – Strengths
CytomX Therapeutics Inc – Weaknesses
CytomX Therapeutics Inc – Opportunities
CytomX Therapeutics Inc – Threats
CytomX Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

CytomX Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

CytomX Therapeutics Inc, Key Information
CytomX Therapeutics Inc, Key Ratios
CytomX Therapeutics Inc, Share Data
CytomX Therapeutics Inc, Major Products and Services
CytomX Therapeutics Inc, History
CytomX Therapeutics Inc, Key Employees
CytomX Therapeutics Inc, Key Employee Biographies
CytomX Therapeutics Inc, Key Operational Heads
CytomX Therapeutics Inc, Other Locations
CytomX Therapeutics Inc, Subsidiaries
CytomX Therapeutics Inc, Key Competitors
CytomX Therapeutics Inc, SWOT Analysis
CytomX Therapeutics Inc, Ratios based on current share price
CytomX Therapeutics Inc, Annual Ratios
CytomX Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[CytomX Therapeutics Inc (CTMX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Stada Arzneimittel AG (SAZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of product …
  • Tobu Railway Co Ltd:企業の戦略・SWOT・財務分析
    Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Maruho Co Ltd:企業の戦略的SWOT分析
    Maruho Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Companhia Energetica de Minas Gerais – CEMIG:企業の戦略・SWOT・財務分析
    Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report Summary Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • United Services Automobile Association:企業の戦略・SWOT・財務情報
    United Services Automobile Association - Strategy, SWOT and Corporate Finance Report Summary United Services Automobile Association - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Essel Propack Limited:戦略・SWOT・企業財務分析
    Essel Propack Limited - Strategy, SWOT and Corporate Finance Report Summary Essel Propack Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Flower Orthopedics Corp:医療機器:M&Aディール及び事業提携情報
    Summary Flower Orthopedics Corp (Flower Orthopedics) is a medical equipment provider that offers orthopedic devices. The company offers instrument kits which include K-wire kits, olive wire kits, guide wire kits, drill bit kits, lag screw kits, cannulated drill bits, trials and cannulated countersin …
  • Great Panther Silver Limited:企業の戦略・SWOT・財務情報
    Great Panther Silver Limited - Strategy, SWOT and Corporate Finance Report Summary Great Panther Silver Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • America’s Car-Mart, Inc. (CRMT):企業の財務・戦略的SWOT分析
    America's Car-Mart, Inc. (CRMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Molinos Rio de la Plata SA (MOLI3):企業の財務・戦略的SWOT分析
    Molinos Rio de la Plata SA (MOLI3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Enlight Renewable Energy Ltd (ENLT):企業の財務・戦略的SWOT分析
    Summary Enlight Renewable Energy Ltd (Enlight Renewable), a subsidiary of Eurocom Group, is a renewable energy company that invests, develops, finances, constructs, operates and manages electricity production projects from renewable energy sources. The company develops photovoltaic technology by whi …
  • Innate Pharma SA (IPH):企業の財務・戦略的SWOT分析
    Summary Innate Pharma SA (Innate Pharma) is a biotechnology company developing antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory hairy cell leukemia (HCL). The company is investigating drugs against …
  • CGN Power Co Ltd (1816):電力:M&Aディール及び事業提携情報
    Summary CGN Power Co Ltd (CGN Power) a subsidiary of China General Nuclear Power Corp, is an electric utility. It generates and sells nuclear power and provides services. The company produces electricity using nuclear source. Under electricity sales contracts, CGN Power sells energy. It also has int …
  • Zenotech Laboratories Ltd (532039):企業の財務・戦略的SWOT分析
    Zenotech Laboratories Ltd (532039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Aprecia Pharmaceuticals Company:製薬・医療:M&Aディール及び事業提携情報
    Summary Aprecia Pharmaceuticals Company (Aprecia) is a drug delivery technology platform company that develops pharmaceutical drug products. The company offers Zipdose technology, a delivery platform that serves as the foundation of orodispersible formulations of prescribed high-dose medications. It …
  • Talktalk Telecom Group PLC (TALK):企業の戦略的SWOT分析
    Talktalk Telecom Group PLC (TALK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Rigaku Corporation:企業の戦略・SWOT・財務情報
    Rigaku Corporation - Strategy, SWOT and Corporate Finance Report Summary Rigaku Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Symrise AG (SY1):企業の財務・戦略的SWOT分析
    Symrise AG (SY1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Harvard Stem Cell Institute-製薬・医療分野:企業M&A・提携分析
    Summary Harvard Stem Cell Institute (HSCI), a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, cor …
  • CHC Group Ltd:企業の戦略的SWOT分析
    CHC Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆